Your session is about to expire
← Back to Search
Autologous Chondrocyte Implantation
CartiLife® for Osteoarthritis and Articular Cartilage Injury
Phase 2
Recruiting
Research Sponsored by Biosolution Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 0 (pre-operation), and up to 24 months (post-operation)
Awards & highlights
Study Summary
This trial is testing whether a treatment for knee cartilage defects is safe and effective.
Eligible Conditions
- Articular Cartilage Injury
- Osteoarthritis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ week 0 (pre-operation), and up to 24 months (post-operation)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 0 (pre-operation), and up to 24 months (post-operation)
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Knee
Cartilage
Secondary outcome measures
Change in IKDC (International Knee Documentation Committee) Score
Knee
Knee
+10 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: CartiLife®Experimental Treatment1 Intervention
Extracellular matrix-associated autologous chondrocytes comprise CartiLife®, composed as pellets (1.1 to 1.8 mm in diameter) in suspension. One pre-filled syringe is implanted per 1 cm3 of defect volume, and fibrin adhesive is applied to fix pellets in place through minimal arthrotomy.
Find a Location
Who is running the clinical trial?
Biosolution Co., Ltd.Lead Sponsor
4 Previous Clinical Trials
159 Total Patients Enrolled
Jungsun Lee, Ph.DStudy DirectorBiosolution Co., Ltd.
1 Previous Clinical Trials
104 Total Patients Enrolled
Media Library
Research Study Groups:
This trial has the following groups:- Group 1: CartiLife®
Share this study with friends
Copy Link
Messenger